US judge declines to intervene in fray because process ‘is creating value for Metsera stockholders’
Novo and Metsera deny Pfizer’s arguments
FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
Reforms, faster development and lower costs have turbocharged growth
Deal for specialist in rare diseases is biggest acquisition under chief executive Vas Narasimhan
The sector is still well off its peak and far behind its Chinese rivals
Scientists are trying to prove whether plasma can slow ageing
An FT series on the science and business of longevity
Pharmaceutical company is latest to invest in artificial intelligence to speed drug development
UK innovators too often have to find capital in the US — the quid pro quo is often jobs and facilities there instead of here
Cambridge-based LinkGevity focuses on preventing the process of necrosis
The $3bn launch of Altos Labs sparked serious interest in longevity but the sector awaits its breakthrough moment
Argo Biopharma collaboration adds to record total this year spent by big pharma on treatments from Chinese companies
Lift BioSciences hopes to use cells from people with unusually strong immune system
Food and Drug Administration reinstates Vinay Prasad who left agency in July after social media campaign
Gordon Sanghera co-founded UK biotech that developed handheld technology for sequencing DNA
Shares in rare disease biotech surge 26% following approach by Swiss group
Germany’s HMNC Brain Health says approach identifies patients most likely to benefit from its drug
Drugmakers increasingly rely on medicines made in China even as the country faces Trump’s tariffs
Focusing relentlessly on low drug costs is the wrong approach
Group reports strong revenues and ‘favourable foreign exchange’ rates in second quarter
Sector returns are over 60% this year, with investors impressed by rapid pace of innovation
US pharma giant seeks to expand footprint beyond cancer treatment as its biggest product nears patent cliff
Issues ranging from medicine approval delays to attacks on Harvard research grants knock driver of regional economy
